标题
Rationale for IL-15 superagonists in cancer immunotherapy
作者
关键词
-
出版物
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume -, Issue -, Pages 1-5
出版商
Informa UK Limited
发表日期
2020-03-11
DOI
10.1080/14712598.2020.1738379
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy
- (2019) Karin M. Knudson et al. Journal for ImmunoTherapy of Cancer
- The γc Family of Cytokines: Basic Biology to Therapeutic Ramifications
- (2019) Warren J. Leonard et al. IMMUNITY
- An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck
- (2019) Ashley Pinette et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
- (2018) Rizwan Romee et al. BLOOD
- An IL-15 superagonist/IL-15Rα fusion complex protects and rescues NK cell-cytotoxic function from TGF-β1-mediated immunosuppression
- (2018) Rika Fujii et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models
- (2018) Bai Liu et al. CYTOKINE
- Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques
- (2018) Cristina Bergamaschi et al. CYTOKINE
- ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
- (2018) John M Wrangle et al. LANCET ONCOLOGY
- Superagonist IL-15-armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade
- (2018) Stacy J. Kowalsky et al. MOLECULAR THERAPY
- Treatment with native heterodimeric IL-15 increases cytotoxic lymphocytes and reduces SHIV RNA in lymph nodes
- (2018) Dionysios C. Watson et al. PLoS Pathogens
- IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages
- (2018) Meili Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex
- (2018) Caroline Jochems et al. OncoImmunology
- The potential and promise of IL-15 in immuno-oncogenic therapies
- (2017) Tanya O. Robinson et al. IMMUNOLOGY LETTERS
- NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
- (2016) D. H. Charych et al. CLINICAL CANCER RESEARCH
- A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses
- (2016) Bai Liu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- IL-15Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists
- (2016) Mélanie Desbois et al. JOURNAL OF IMMUNOLOGY
- IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas
- (2016) Peter S. Kim et al. Oncotarget
- The IL-15-Based ALT-803 Complex Enhances Fc RIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas
- (2015) M. Rosario et al. CLINICAL CANCER RESEARCH
- Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
- (2015) Kevin C. Conlon et al. JOURNAL OF CLINICAL ONCOLOGY
- The Shared and Contrasting Roles of IL2 and IL15 in the Life and Death of Normal and Neoplastic Lymphocytes: Implications for Cancer Therapy
- (2015) T. A. Waldmann Cancer Immunology Research
- Characterization and Favorablein VivoProperties of Heterodimeric Soluble IL-15·IL-15Rα Cytokine Compared to IL-15 Monomer
- (2013) Elena Chertova et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI
- (2013) Marie Vincent et al. OncoImmunology
- Fc-fusion proteins: new developments and future perspectives
- (2012) Daniel M. Czajkowsky et al. EMBO Molecular Medicine
- IL-15:IL-15 receptor alpha superagonist complex: High-level co-expression in recombinant mammalian cells, purification and characterization
- (2011) Kai-ping Han et al. CYTOKINE
- High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor fusion protein, in metastatic melanoma and colorectal cancer
- (2009) A. Bessard et al. MOLECULAR CANCER THERAPEUTICS
- Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer
- (2009) M. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Interleukin-15/Interleukin-15R Complexes Promote Destruction of Established Tumors by Reviving Tumor-Resident CD8+ T Cells
- (2008) M. Epardaud et al. CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More